SoftOx Solutions AS (OSL:SOFTX)

Market Cap	311.25M +33.6%
Revenue (ttm)	15.58M +96.9%
Net Income	-10.81M
EPS	-0.00
Shares Out	2.56B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,638,340
Average Volume	37,475,727
Open	0.1200
Previous Close	0.1170
Day's Range	0.1172 - 0.1294
52-Week Range	0.0490 - 0.1658
Beta	0.98
RSI	59.11
Earnings Date	May 27, 2026

About SoftOx Solutions AS

SoftOx Solutions AS, together with its subsidiaries, operates as a clinical-stage pharmaceutical company that develops antimicrobials products for infection prevention and treatment in Norway. The company develops SoftOx Inhalation Solution, an inhalation solution that is phase II clinical trial for the treatment of ventilator associated pneumonia and other airway infections. It also developing pan antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. SoftOx Solutions AS was founded in 2012 and is headquartered in Fornebu, Norwa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 2
• Stock Exchange: Oslo Børs
• Ticker Symbol: SOFTX

Financial Performance

In 2025, SoftOx Solutions AS's revenue was 15.58 million, an increase of 96.92% compared to the previous year's 7.91 million. Losses were -10.81 million, -74.82% less than in 2024.